Next earnings date: 28 Aug 2025

Can-Fite BioPharma Ltd. – AMEX:CANF
Can-Fite BioPharma Ltd. stock price today
Can-Fite BioPharma Ltd. stock price monthly change
Can-Fite BioPharma Ltd. stock price quarterly change
Can-Fite BioPharma Ltd. stock price yearly change
Can-Fite BioPharma Ltd. key metrics
Market Cap | 9.08M |
Enterprise value | 4.26M |
P/E | -0.57 |
EV/Sales | 4.69 |
EV/EBITDA | -0.37 |
Price/Sales | 8.71 |
Price/Book | 1.06 |
PEG ratio | -0.04 |
EPS | -1.81 |
Revenue | 743K |
EBITDA | -8.19M |
Income | -7.47M |
Revenue Q/Q | -21.31% |
Revenue Y/Y | -8.27% |
Profit margin | -1247.41% |
Oper. margin | -1241.58% |
Gross margin | 0% |
EBIT margin | -1241.58% |
EBITDA margin | -1102.96% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCan-Fite BioPharma Ltd. stock price history
Can-Fite BioPharma Ltd. stock forecast
Can-Fite BioPharma Ltd. financial statements
Mar 2023 | 196K | -2.38M | -1218.37% |
---|---|---|---|
Jun 2023 | 196K | -1.67M | -852.04% |
Sep 2023 | 196K | -1.76M | -898.98% |
Dec 2023 | 155K | -1.65M | -1065.81% |
2025 | 900K | -4.72M | -525.54% |
---|---|---|---|
2026 | 800K | -213.05K | -26.63% |
2027 | 43.34M | 4.98M | 11.5% |
2028 | 310.88K | 9.97M | 3207.35% |
Analysts Price target
Financials & Ratios estimates
2024-06-27 | -0.4 | -0.65 |
---|---|---|
2024-09-26 | -0.4 | -0.4 |
2024-12-05 | -0.27 | -0.27 |
Payout ratio | 0% |
---|
2019 | |
---|---|
2020 | |
2021 | 0.01% |
2022 | 0.05% |
2023 |
Mar 2023 | 13489000 | 4.99M | 37.04% |
---|---|---|---|
Jun 2023 | 11032000 | 4.15M | 37.69% |
Sep 2023 | 9169000 | 3.93M | 42.91% |
Dec 2023 | 9989000 | 3.74M | 37.5% |
Mar 2023 | 0 | 0 | 0 |
---|---|---|---|
Jun 2023 | 95K | 0 | 0 |
Sep 2023 | 0 | 0 | 0 |
Dec 2023 | 0 | 0 | 0 |
Can-Fite BioPharma Ltd. alternative data
Aug 2023 | 8 |
---|---|
Sep 2023 | 8 |
Oct 2023 | 8 |
Nov 2023 | 8 |
Dec 2023 | 8 |
Jan 2024 | 8 |
Feb 2024 | 8 |
Mar 2024 | 8 |
Apr 2024 | 8 |
May 2024 | 8 |
Jun 2024 | 8 |
Jul 2024 | 8 |
Can-Fite BioPharma Ltd. other data
Patent |
---|
Grant Filling date: 26 Aug 2020 Issue date: 5 Apr 2022 |
Application Filling date: 5 Jan 2020 Issue date: 17 Mar 2022 |
Application Filling date: 16 Sep 2018 Issue date: 11 Mar 2021 |
Application Filling date: 26 Aug 2020 Issue date: 10 Dec 2020 |
Grant Filling date: 22 May 2018 Issue date: 22 Sep 2020 |
Quarter | Transcript |
---|---|
Q3 2020 30 Nov 2020 | Q3 2020 Earnings Call Transcript |
Q2 2020 28 Aug 2020 | Q2 2020 Earnings Call Transcript |
Q1 2020 1 Jun 2020 | Q1 2020 Earnings Call Transcript |
Insider | Compensation |
---|---|
Dr. Pnina Fishman Ph.D. (1948) Scientific Founder, Chief Executive Officer & Director | $598,000 |
Mr. Motti Farbstein (1964) Chief Operating & Financial Officer | $415,000 |
Dr. Sari Fishman Ph.D. (1972) Vice President of Bus. Devel. | $286,000 |
-
What's the price of Can-Fite BioPharma Ltd. stock today?
One share of Can-Fite BioPharma Ltd. stock can currently be purchased for approximately $0.65.
-
When is Can-Fite BioPharma Ltd.'s next earnings date?
Can-Fite BioPharma Ltd. is estimated to report earnings on Thursday, 28 Aug 2025.
-
Does Can-Fite BioPharma Ltd. pay dividends?
No, Can-Fite BioPharma Ltd. does not pay dividends.
-
How much money does Can-Fite BioPharma Ltd. make?
Can-Fite BioPharma Ltd. has a market capitalization of 9.08M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 8.27% to 743K US dollars. Can-Fite BioPharma Ltd. made a loss 7.63M US dollars in net income (profit) last year or -$0.27 on an earnings per share basis.
-
What is Can-Fite BioPharma Ltd.'s stock symbol?
Can-Fite BioPharma Ltd. is traded on the AMEX under the ticker symbol "CANF".
-
What is Can-Fite BioPharma Ltd.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Can-Fite BioPharma Ltd.?
Shares of Can-Fite BioPharma Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Can-Fite BioPharma Ltd.'s key executives?
Can-Fite BioPharma Ltd.'s management team includes the following people:
- Dr. Pnina Fishman Ph.D. Scientific Founder, Chief Executive Officer & Director(age: 77, pay: $598,000)
- Mr. Motti Farbstein Chief Operating & Financial Officer(age: 61, pay: $415,000)
- Dr. Sari Fishman Ph.D. Vice President of Bus. Devel.(age: 53, pay: $286,000)
-
Is Can-Fite BioPharma Ltd. founder-led company?
Yes, Can-Fite BioPharma Ltd. is a company led by its founder Dr. Pnina Fishman Ph.D..
-
How many employees does Can-Fite BioPharma Ltd. have?
As Jul 2024, Can-Fite BioPharma Ltd. employs 8 workers.
-
When Can-Fite BioPharma Ltd. went public?
Can-Fite BioPharma Ltd. is publicly traded company for more then 12 years since IPO on 6 Nov 2012.
-
What is Can-Fite BioPharma Ltd.'s official website?
The official website for Can-Fite BioPharma Ltd. is canfite.com.
-
How can i contact Can-Fite BioPharma Ltd.?
Can-Fite BioPharma Ltd. can be reached via phone at +972 3 924 1114.
Can-Fite BioPharma Ltd. company profile:

Can-Fite BioPharma Ltd.
canfite.comAMEX
8
Biotechnology
Healthcare
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
Petah Tikva, 4951778
CIK: 0001536196
ISIN: US13471N3008
CUSIP: 13471N201